Becton, Dickinson and Co (XSWX:BDX)
CHF 243.41 0 (0%) Market Cap: 63.44 Bil Enterprise Value: 78.37 Bil PE Ratio: 37.37 PB Ratio: 2.48 GF Score: 85/100

Becton Dickinson and Co at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 01:00PM GMT
Matthew Stephan Miksic
Barclays Bank PLC, Research Division - Research Analyst

All right. Well, good morning, everybody. My name is Matt Miksic at Barclays. I cover U.S. Medical Devices. We're super pleased to have with us this morning part of the management team here from Becton, Dickinson. We have Chris DelOrefice, EVP and CFO; and Dave Hickey, EVP and President of Life Sciences.

I wanted to first thank you both for coming. And it's my first year at this conference and it's been great so far. I wanted to take sort of like a little bit of a higher level view of the company, kind of step through what's driving the growth and what's driving the margin benefits that you've been able to deliver, in part because on the growth side, for a traditional Becton, Dickinson, I think a lot of people have been surprised, intrigued, and maybe a little skeptical that you can maintain this kind of higher tier of growth that you've started to deliver in the last couple of years.

And then on the margin side, I think it's notable that in the landscape of medical device companies that are all facing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot